Related Experiment Video
Updated: May 15, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
Published on: January 5, 2024
The fibromyalgia family study: a genome-wide linkage scan study
Lesley M Arnold1, Jinbo Fan, I Jon Russell
1Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio 44106, USA. Lesley.Arnold@uc.edu
Fibromyalgia has a strong genetic component, with a sibling recurrence risk ratio of 13.6. This study identified suggestive genetic linkage on chromosome 17p11.2-q11.2, warranting further research into fibromyalgia susceptibility loci.
Area of Science:
- Genetics
- Rheumatology
- Medical Genomics
Background:
- Familial aggregation of fibromyalgia suggests a genetic basis for the condition.
- Previous research has increasingly recognized the hereditary component of fibromyalgia.
Purpose of the Study:
- To conduct a genome-wide linkage scan to identify susceptibility loci for fibromyalgia.
- To investigate the genetic underpinnings of fibromyalgia in affected families.
Main Methods:
- Utilized a genome-wide linkage scan on 116 families from the Fibromyalgia Family Study.
- Employed model-free linkage analysis with 341 microsatellite markers and the Haseman-Elston regression approach.
Main Results:
- Observed a high sibling recurrence risk ratio (λs) of 13.6 for fibromyalgia.
- Identified genome-wide suggestive linkage on chromosome 17p11.2-q11.2 at markers D17S2196 and D17S1294.
Conclusions:
- The findings strongly suggest a significant genetic contribution to fibromyalgia.
- This study is the first to report genome-wide suggestive linkage to the 17p11.2-q11.2 region for fibromyalgia.
- Further investigation in multicase families is recommended to pinpoint causal risk variants.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets